[1] |
WU Zhibai, XU Guiqin, ZHANG Li, YANG Zhaojuan, LIU Yun, JIAO Kun, CHEN Zehong, XU Chen, ZUO You, ZHENG Ningqian, YE Zhiqian, LIU Yongzhong.
Mechanism study of KCMF1 promoting proliferation and NF-κB signaling transduction in colorectal cancer cells
[J]. China Oncology, 2024, 34(11): 987-997.
|
[2] |
XUE Liqiong, GUO Ye, CHEN Libo.
Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer (2023 edition)
[J]. China Oncology, 2023, 33(9): 879-888.
|
[3] |
YUAN Xinyue, YAO Yao, CHENG Shuai, ZHENG Xin, ZHANG Yuan.
Clinical study on high-risk factors for contralateral lymph node metastasis in unilateral papillary thyroid carcinoma
[J]. China Oncology, 2023, 33(6): 619-628.
|
[4] |
QU Ning, WANG Yuting, MA Ben, WANG Yu.
Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022
[J]. China Oncology, 2023, 33(5): 423-430.
|
[5] |
CHEN Hong, CHEN Junxia.
Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism
[J]. China Oncology, 2023, 33(4): 342-353.
|
[6] |
SUN Di, SUN Yuqing, ZHANG Xin, HUANG Lisha, LIN Yansong.
The relationship between genetic characteristics and clinical characteristics and the efficacy of 131I therapy in children and adolescents with locally advanced or metastatic differentiated thyroid cancer
[J]. China Oncology, 2022, 32(5): 380-387.
|
[7] |
DENG Shuting, FENG Yuan, QIAN Kai, GUO Kai, WANG Zhuoying.
Meta-analysis of the association between gene alterations and distant metastasis of differentiated thyroid carcinoma in children and adolescents
[J]. China Oncology, 2022, 32(5): 388-396.
|
[8] |
LIU Jia, LI Guanghan, GAO Luying, ZHANG Zijie, WANG Ying, XIONG Ying, ZHANG Bo.
Establishment and test of graded diagnostic model of thyroid cancer in children and adolescents
[J]. China Oncology, 2022, 32(5): 397-403.
|
[9] |
GUO Wenting, MU Zhuanzhuan, LI Zheng, ZHANG Yingqiang, JIN Xiaona, LIN Yansong.
Clinical outcome of 131I therapy in differentiated thyroid cancer patients with suspicious high thyroglobulin concentration
[J]. China Oncology, 2022, 32(5): 410-416.
|
[10] |
Diao Xinfeng, Li Xinmao, Hou Liang, Wei Zhixuan.
YTHDF2 promotes progression of glioblastoma via inducing mRNA decay of IGFBP7 and activating PI3K/AKT signaling pathway
[J]. China Oncology, 2022, 32(3): 218-227.
|
[11] |
MEI Xiaoran, FENG Fang, WANG Hui, WEI Zhixiao.
Analysis of therapeutic response of iodine positive metastasis lymph nodes in differentiated thyroid cancer after 131I treatment
[J]. China Oncology, 2022, 32(11): 1091-1097.
|
[12] |
CAO Dalong, YE Dingwei.
New trends and future prospects of regulatory cell death in renal carcinoma
[J]. China Oncology, 2022, 32(10): 1000-1006.
|
[13] |
CHEN Yifan, SHEN Yihui, CHENG Leilei, LIN Jinyi, ZHANG Hui, WANG Xuejun, XU Yuchen, ZHANG Jian, GE Junbo.
Different preventive effects of four cardioprotective agents on mice with adriamycin-induced cardiotoxicity
[J]. China Oncology, 2022, 32(10): 936-947.
|
[14] |
LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun .
miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene
[J]. China Oncology, 2021, 31(7): 581-588.
|
[15] |
CAO Dalong, ZHU Wenkai, SHI Guohai, ZHANG Hailiang, WANG Ziliang, YE Dingwei.
The influence of PRUNE2 gene point mutation on proliferation, apoptosis, invasion and migration of prostate cancer DU145 cells
[J]. China Oncology, 2021, 31(6): 441-446.
|